1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €12.08 (+173.92%). The median is €11.22 (+154.42%).
| Buy |
24 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 1.99M | 73.03% |
| Gross profit | 1.99M | 63.92% |
| Net profit | -60.77M | 41.92% |
| EBITDA | -62.4M | 52.37% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €866.52M |
Number of shares | 197.05M |
52-week high/low | €18.76 - €4.32 |
| Dividends | No |
Beta | -1.29 |
P/E ratio | -4.67 |
PEG ratio | 0.09 |
P/B ratio | 2.27 |
P/S ratio | 15.36 |
Company profile
| Name | WAVE Life Sciences |
| CEO | Paul Bolno |
| Employees | 317 |
Deep Dive
Discover assets
Shareholders of WAVE Life Sciences also invest in the following assets
